Jatenzo in Children Under 12: Developmental Impact and Safety Considerations

Why Jatenzo Is Not Used in Children Under 12

Jatenzo is FDA-approved exclusively for adult males 18 and older with conditions associated with deficient endogenous testosterone production. The prescribing label explicitly lists pediatric use as a contraindication, and no clinical trial has enrolled children under 12 in a Jatenzo study. Understanding what that means in practice requires a clear look at what exogenous androgens actually do to a developing body.

FDA Labeling and the Contraindication Basis

The FDA approved Jatenzo in March 2019 after reviewing data from two open-label trials (Study 1, N=166; Study 2, N=106) that enrolled only adult males. [1] The full prescribing information states: "Jatenzo is contraindicated in: patients less than 18 years of age." [1] This is not a precautionary hedge. It is a hard contraindication based on the known pharmacology of testosterone in immature physiological systems.

The contraindication reflects a body of endocrinology literature showing that supraphysiologic or even low-dose exogenous androgens in pre-pubertal children accelerate skeletal maturation faster than linear growth. The result is a shorter final adult height. [2]

What "Contraindicated" Means Clinically

A contraindication in FDA labeling means the drug must not be used in that population under any circumstances recognized by the approved indication. Prescribers who administer Jatenzo to a child under 12 would be operating entirely outside the approved label, without any safety or efficacy data, and exposing the patient to risks the manufacturer has explicitly flagged. Medical liability and patient harm converge here.

How Exogenous Testosterone Affects the Developing Body

Children under 12 are almost entirely pre-pubertal. The hypothalamic-pituitary-gonadal (HPG) axis is in a quiescent phase from roughly age 2 until the onset of puberty, typically around age 9 to 11 in girls and 10 to 12 in boys. [3] Introducing exogenous testosterone into this quiescent axis produces a cascade of effects that differ sharply from adult responses.

Bone Age Acceleration and Epiphyseal Closure

The best-documented pediatric androgen risk is accelerated bone maturation. Growth plates (epiphyses) are cartilaginous zones where long bones elongate. Androgens dose-dependently stimulate epiphyseal maturation; once the plates fuse, linear growth stops permanently. [4]

In a landmark analysis published in JCEM, boys with idiopathic short stature who received testosterone enanthate 25 mg IM monthly showed bone age advancing 1.3 years for every 12 months of treatment, outpacing chronological age advancement. [4] Oral testosterone undecanoate produces comparable androgenic exposure through different pharmacokinetics, and there is no physiological reason to expect a safer bone-age profile.

The practical consequence: a 9-year-old whose bone age advances 18 months in 12 months of androgen exposure may lose 2 to 4 cm of final adult stature, a loss that is biologically irreversible. [5]

Hypothalamic-Pituitary-Gonadal Axis Suppression

Before puberty, the HPG axis is suppressed by a combination of intrinsic hypothalamic restraint and low sex steroid feedback. Exogenous androgens deliver testosterone feedback to the hypothalamus and anterior pituitary, suppressing GnRH pulse frequency and reducing LH and FSH secretion. [3]

In adults, this suppression is the pharmacological basis for hypogonadal recovery after testosterone cessation, though recovery can take 6 to 18 months. In children, the HPG axis has not yet completed its programmed developmental activation. Suppressing it with exogenous androgens before that activation occurs could delay or disrupt the normal pubertal timing sequence. [3]

No randomized trial has tested this in children under 12 with Jatenzo, and none should. The ethical barriers to such a trial are insurmountable.

Virilization in Pre-Pubertal Children

Even brief androgen exposure in pre-pubertal children causes virilization: pubic hair growth, penile or clitoral enlargement, acne, adult body odor, and accelerated linear growth followed by premature growth arrest. The FDA MedWatch database includes pediatric virilization cases linked primarily to accidental contact with testosterone gels used by adult male caregivers. [6] A 2009 FDA public health advisory specifically warned of virilization in children from secondary exposure to testosterone gels. [6]

Jatenzo is an oral formulation, reducing secondary contact risk compared to gels. But intentional administration would produce the same or greater androgenic effect per dose.

Cardiovascular and Hematologic Considerations

Jatenzo carries a black-box warning for blood pressure elevation in adults. In Study 1 (N=166), 21% of adult men experienced a mean increase in systolic blood pressure of 3.5 mmHg, and 5% had increases exceeding 20 mmHg. [1] Pediatric cardiovascular physiology differs from adult physiology. Blood pressure norms, cardiac mass, and arterial compliance are all age-dependent. There are no data on how these blood pressure effects would translate to a child under 12, but the adult signal alone reinforces the contraindication.

Testosterone also stimulates erythropoiesis, raising hematocrit. In adults, Jatenzo label data show hematocrit exceeding 54% in a subset of patients. [1] Polycythemia in a child whose normal hematocrit range is narrower creates thrombotic risk that is both predictable and unacceptable.

Pharmacokinetics of Oral Testosterone Undecanoate in Context

Jatenzo (testosterone undecanoate 158 mg, 198 mg, or 237 mg soft gel capsules) is absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism. [1] Peak testosterone levels (Cmax) in adult Study 1 participants averaged 1,083 ng/dL at steady state with the 237 mg twice-daily dose. [1]

Why Adult PK Data Cannot Be Extrapolated to Children Under 12

Body weight, body fat distribution, lymphatic transport capacity, and sex hormone-binding globulin (SHBG) levels all differ substantially between prepubertal children and adult men. A prepubertal boy weighing 25 to 35 kg has a far smaller volume of distribution. The same capsule dose that produces 1,083 ng/dL in a 90 kg adult male would produce dramatically higher weight-adjusted testosterone concentrations in a small child.

Pre-pubertal testosterone reference ranges are 3 to 10 ng/dL. [3] Any oral testosterone undecanoate dose formulated for adults would produce testosterone levels hundreds of times above physiological for that age group. No safe pediatric dose for Jatenzo has been established, and none can be inferred from adult data.

Comparison to Other Testosterone Formulations in Pediatric Practice

In legitimate delayed puberty management, pediatric endocrinologists use low-dose testosterone enanthate or testosterone cypionate by intramuscular injection, starting at 25 to 50 mg IM monthly, in boys 14 years and older with confirmed constitutional delay. [7] This approach is supported by the Pediatric Endocrine Society and Endocrine Society guidelines. [7] Dose and duration are tightly monitored with 6-month bone age X-rays.

Jatenzo has no role in this practice. It was not designed for it, has not been tested for it, and the capsule doses available (158 mg, 198 mg, 237 mg) are orders of magnitude higher than what any legitimate delayed puberty protocol would consider in a young adolescent, let alone a pre-pubertal child.

Accidental Pediatric Exposure: Recognition and Response

The more clinically relevant scenario for children under 12 is not intentional prescribing but accidental exposure. While Jatenzo's oral route makes gel-transfer exposure impossible, a caregiver's capsule left within a child's reach represents a potential ingestion exposure.

Clinical Signs of Accidental Androgen Exposure

The Endocrine Society's clinical practice guideline on androgen use notes that signs of androgen excess in pre-pubertal children appear within days to weeks of significant exposure. [8] These include:

• Rapid onset of pubic or axillary hair
• Penile enlargement in boys or clitoral enlargement in girls
• Acne on the face, chest, or back
• Acceleration in linear growth velocity
• Aggressive or mood-altered behavior

Any child presenting with these signs should trigger an immediate history review of caregiver medications.

Emergency and Monitoring Response

If a child under 12 is suspected to have ingested testosterone undecanoate, poison control (1-800-222-1222 in the US) should be contacted immediately. Clinical evaluation should include serum total testosterone, LH, FSH, estradiol, bone age X-ray (left wrist and hand), and a full height/weight growth chart review. [8]

Accidental single-dose ingestion may not produce lasting effects, but prolonged or repeated exposure requires urgent pediatric endocrinology consultation to assess HPG axis suppression and bone age advancement.

A staged response framework for clinicians:

1. Confirm exposure history and estimate total androgen dose.
2. Obtain testosterone, LH, FSH, estradiol, and DHEAS within 24 hours.
3. Order bone age X-ray (left hand/wrist, Greulich-Pyle method) at baseline.
4. Refer to pediatric endocrinology within 1 to 2 weeks.
5. Repeat bone age X-ray at 6 months if baseline was advanced for chronological age.
6. Counsel caregivers on secure medication storage to prevent recurrence.

Regulatory and Guideline Context

Endocrine Society Position

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men states: "We recommend against testosterone therapy in men with...age less than 18 years." [8] The same guideline, authored by Shalender Bhasin et al., underscores that pediatric testosterone use is restricted to narrow indications managed exclusively by pediatric endocrinologists, using formulations and doses supported by trial data, none of which include Jatenzo.

The guideline further specifies: "Clinicians should assess serum testosterone and bone age every 6 months during androgen treatment in adolescents to avoid compromising adult height." [8] This standard applies even to legitimate adolescent use. For children under 12, the threshold for any testosterone treatment is essentially nonexistent outside rare, severe congenital hypogonadism managed at specialist centers.

FDA Adverse Event Reporting

The FDA's 2009 public health advisory on testosterone gel secondary exposure documented 20 pediatric cases of virilization, prompting a black-box warning on all testosterone gel products. [6] The advisory noted cases in children as young as 9 months. While Jatenzo's oral formulation eliminates skin-contact transfer, the FDA advisory reinforced the broader principle that testosterone products of any type require child-safe storage and must never be administered to pre-pubertal children.

Growth Hormone Interaction Concerns

Children under 12 who have growth hormone deficiency (GHD) or are receiving recombinant human growth hormone (rhGH) represent a particularly vulnerable subgroup. Androgens and growth hormone interact at the level of IGF-1 production. Low-dose androgens can transiently amplify GH secretion, but supraphysiologic androgen levels suppress pulsatile GH release through negative feedback on hypothalamic GHRH neurons. [5] Administering Jatenzo-level testosterone doses to a GHD child receiving rhGH therapy would likely counteract the therapeutic intent of the growth hormone treatment while accelerating bone age.

Summary of Absolute Contraindications and Risk Hierarchy

Children under 12 face at least four distinct, independent mechanisms of harm from exogenous testosterone at Jatenzo doses:

1. Premature epiphyseal fusion with irreversible growth stunting (highest-certainty risk, documented in pediatric androgen trials). [4]
2. HPG axis suppression disrupting the programmed onset of puberty. [3]
3. Virilization producing irreversible secondary sex characteristics inappropriate for age. [6]
4. Cardiovascular stress from androgen-driven blood pressure elevation and erythrocytosis in a cardiovascular system not yet at adult baseline. [1]

None of these risks have a dose threshold established for children under 12. None of them can be managed by dose adjustment because no safe dose of Jatenzo exists in this population. The drug's contraindication is not a regulatory technicality. It reflects the biological reality that introducing adult-dose exogenous testosterone into a pre-pubertal body causes harm with high certainty and no established benefit.

Prescribers encountering a patient under 12 who needs evaluation for androgen deficiency should refer to a board-certified pediatric endocrinologist and consider only formulations with established pediatric safety profiles, administered under guideline-directed monitoring protocols that include baseline and serial bone age imaging.